Abstract The purpose of this study was to determine the serotypes, genotypes and antimicrobial susceptibilities of Streptococcus pneumoniae causing otitis media (OM) in children in Dublin, Ireland. S. pneumoniae isolates (n=28) from spontaneously discharging OM were studied. Serotyping was performed using a previously undescribed multiplex polymerase chain reaction (PCR) scheme in combination with serological methods. Multilocus sequence typing (MLST) was performed using standard procedures. Antimicrobial susceptibility testing was performed using the Etest method. Fourteen different S. pneumoniae serotypes were identified. The five most common serotypes were 3, 19F, 19A, 14 and 6A, which accounted for 68% of all infections. The 7-valent pneumococcal conjugate vaccine (PCV7), 10-valent pneumococcal conjugate vaccine (PHiD-CV) and 13-valent pneumococcal conjugate vaccine (PCV13) provided potential coverages of 43%, 46% and 86%, respectively. Reduced susceptibility to penicillin was evident for 25% of isolates and was associated with serotypes 14, 19A, 19F and 9V. A total of 21 different sequence types (STs) were identified. Pneumococcal Molecular Epidemiology Network (PMEN) clones or their variants represented 54% (15/28) of all isolates. Continued monitoring and characterisation of S. pneumoniae causing OM in Ireland is warranted in order to guide future vaccine and treatment policies.
Introduction
Streptococcus pneumoniae is one of the leading causes of otitis media (OM) in children and is responsible for approximately 38% of all cases worldwide [1] . The majority (83%) of children less than 3 years of age experience at least one episode of OM [2] . The cost of outpatient visits and treatments due to OM is considerably high, with an estimated expense of $2-5 billion per annum in the United States (US). The 7-valent pneumococcal conjugate vaccine (PCV7; Prevenar 7™) was or continues to be routinely administered to young children in a number of countries. An overall reduction of 6% and 8.9% in clinical OM incidence was demonstrated in Finnish and US infants, respectively, following immunisation with PCV7 [3] . Vaccine efficacy of 10-50% was evident against recurrent OM or for the prevention of tympanostomy tube placement. A decline of 42.7% and 41.9% in OM-associated ambulatory visits and antibiotic prescriptions, respectively, since vaccine introduction in the US was demonstrated by Zhou et al. [2] .
PCV7 was introduced to the infant immunisation programme in Ireland in late 2008. In order to determine the effects and impact of PCV7 in Ireland and, indeed, elsewhere, it is important to have an understanding and knowledge of S. pneumoniae serotypes causing infection. To our knowledge, no data associated with the epidemiology of S. pneumoniae causing OM in Ireland has been documented.
Accurate S. pneumoniae identification is essential for diagnosis and for optimal treatment. Reliable typing systems are important to detect changes in the dominant strains over time. Our group previously developed a multiplex polymerase chain reaction (PCR) assay to identify the seven serotypes contained in PCV7 [4] . Here, we describe a new and improved multiplex PCR scheme for use on lysed single-colony extracts that confirms S. pneumoniae identification and detects an expanded number of serotypes. In addition, we describe the serotypes, genotypes and antimicrobial susceptibilities of S. pneumoniae causing OM in children in Ireland.
Methods

Study population
S. pneumoniae isolated from swabs of spontaneous otological drainage in children with OM, received by the routine microbiology laboratory of the Children's University Hospital, Temple St., Dublin, an acute and tertiary referral paediatric hospital, were included in the study. Between January 2007 and December 2008, 28 S. pneumoniae isolates were identified by traditional microbiological methods following culture on Colombia blood agar plates. PCV7 was introduced to the immunisation programme in Ireland in September 2008, thus, three isolates were recovered after PCV7 introduction.
Bacterial isolates control collection
A control collection (n=144) of S. pneumoniae isolates, whose serotype had been previously determined [5] , were retrieved from storage in 1:3 glycerol (nutrient broth containing 0.5% glucose and 10% glycerol) horse serum storage medium at −70°C. Of these, 132/144 (92%) isolates had remained viable and were available for re-serotyping. An additional control collection of 51 Statens Serum Institute (SSI) (Copenhagen, Denmark) S. pneumoniae strains were also utilised to validate the PCR assays. To ensure accurate S. pneumoniae identification, other organisms used to test the specificity of the assay included wellcharacterised isolates of 21 bacterial species, including S. agalactiae, S. pyogenes, Neisseria meningitidis and Haemophilus influenzae. Additional clinical isolates of viridans group streptococci (n=20) were also assessed to ensure that no cross-reactivity occurred.
DNA preparation
A single colony from a fresh overnight culture grown on Columbia blood (5% sheep blood) agar plates was immersed in 20 μl Microlysis™ Plus (Microzone Ltd., Sussex, UK) and processed according to the manufacturer's guidelines. PCR was then performed on the lysed singlecolony extracts.
Multiplex PCR assembly
All available relevant sequences were aligned using ClustalX, and the appropriate primers (9V-F, 3-R, lytA-F and lytA-R) were determined using Primer Express® (Applied Biosystems, Warrington, UK) software. The lytA primers were designed to target conserved nucleotides in typical lytA alleles, characteristic of pneumococci not present in lytA alleles of mitis group streptococci [6] [7] [8] .
The primer sequences and amplicon size of products were as previously described, with the exception of the final primer concentrations in each reaction mixture; serotypes 4 (0.75 μM) and 14 (0.5 μM) [9] , 6 (0.6 μM) [10] , 18 (0.75 μM), 19F (0.6 μM), 23F (0.75 μM), 1 (0.4 μM), 5 (0.48 μM), 7F (0.64 μM) and cpsA (0.08 μM) [11] . A serotype 9V forward primer was designed (5′-agttcaccttg taacagttatcccata-3′) (0.6 μM) and used in combination with a previously described 9V reverse primer [11] (0.6 μM), which yielded a product of 107 bp. A new serotype 3 reverse primer was also designed (5′-ttctgcccaccttagttgct-3′) (0.4 μM) and used in combination with a previously described forward primer [10] (0.4 μM), which yielded a product of 470 bp. The newly designed lytA forward primer (5′-caactaaagaagagttcatga-3′) (0.1 μM) and lytA reverse primer (5′-ctcgtgcgttttaattccagc-3′) (0.1 μM) yielded a product of 125 bp.
The first multiplex PCR reaction was designed to screen for serotypes contained in PCV7 with the use of cpsA primers as an internal positive control (IPC) [9, 11] (Fig. 1) . The second multiplex PCR reaction was designed to confirm S. pneumoniae identification (lytA) and screen for serotypes 1, 3, 5 and 7F, with cpsA as an IPC.
PCR reaction
Each 25-μl PCR reaction mixture contained the following: 1× reaction buffer (Tris-Cl, KCl, (NH4) 2 SO 4 , 1.5 mM MgCl 2 ; pH 8.7; Qiagen), 1 mM MgCl 2 (Qiagen), 1× Qsolution (Qiagen), 200 μM of each deoxynucleoside triphosphate (Promega Inc.), 2U Hot Star Taq DNA polymerase (Qiagen) and 1 μl of lysed Microlysis® Plus colony extract as the template. Thermocycling was performed on a Peltier Thermal Cycler 200 DNA engine (MJ Research, Waltham, MA, USA) using the following conditions: 95°C for 15 min, followed by 35 cycles at 95°C for 40 s, 55°C for 45 s, 65°C for 150 s and a final extension step at 65°C for 1 min. PCR products (10 μl) were analysed using 3% (w/v) agarose gel electrophoresis with 5 μg/ml ethidium bromide and visualised under UV transillumination. PCR product sizes were compared with the molecular size standard (100-bp DNA Ladder; New England Biolabs, Beverly, MA, USA).
Serotyping
Isolates were serotyped using a combination of the multiplex PCR scheme described above, and/or for those isolates for which the serotype was not determined using the above method, the serotype was determined by serological methods [12] using antisera obtained from the SSI (Copenhagen, Denmark).
DNA isolation and multilocus sequence typing (MLST)
DNA was purified from fresh overnight cultures grown on Columbia blood agar using the Gentra® Puregene® Yeast/ Bact. Kit (Qiagen) according to the manufacturer's guidelines. MLST was performed using the standard procedure to amplify the seven house-keeping genes as previously described [13] . Allele numbers and sequence types (STs) were assigned and eBURST analysis performed using http://www.mlst.net/. Genetically related clones were either single-locus variants (SLVs) or double-locus variants (DLVs) of a specific clone. STs were compared with those of the Pneumococcal Molecular Epidemiology Network (PMEN) clones available at http://www.sph.emory.edu/PMEN/.
Antimicrobial susceptibility
Isolates were tested for susceptibility to penicillin, cefotaxime, erythromycin, clindamycin and tigecycline using the Etest (AB bioMérieux, Solna, Sweden) method and the results were interpreted following Clinical and Laboratory Standards Institute (CLSI) guidelines [14] . Susceptibility to penicillin was defined as follows: susceptible, minimum inhibitory concentration (MIC)≤0.06 μg/ml; intermediate, 0.12-1 μg/ml; and high-level-resistant, ≥2 μg/ml; corresponding to the new oral penicillin breakpoints. Isolates with reduced susceptibility to three antibiotics or more were considered to be multidrugresistant (MDR).
Results
Multiplex PCR validation
The multiplex PCR reactions correctly identified 73.5% (97/132) of serotypes in the control collection of isolates (Table 1) . Three discrepancies did occur. However, repeat assessment confirmed the PCR result as being accurate. The cpsA primers (the IPC) were consistently positive for all isolates and the 90 pneumococcal serotypes tested (Fig. 1) . Exceptions included a lack of reactivity with isolates harbouring the type 25A, 25F and 38 capsule, as previously observed [15] . The lytA primers consistently and specifically amplified all pneumococci tested, with no cross-reactivity with other organisms identified.
Patient characteristics
Twenty-eight cases of OM caused by S. pneumoniae were identified in children, with age ranging from 23 days to 9 years. The majority (68%) of infections occurred in children <3 years of age. The male:female ratio was 1.5:1.
Serotype distribution
A total of 14 different S. pneumoniae serotypes were identified. The most common serotypes were 3 (n=5) and 19F (n=5), followed by 19A (n=3), 14 (n=3) and 6A (n=3). These five serotypes together accounted for 68% of infections overall. Three isolates caused infection after PCV7 introduction: one expressed vaccine serotype 14, another expressed vaccine serotype 9V and the third isolate expressed serotype 6A. The potential coverage provided by PCV7 with all of the age groups included was 43%, for PHiD-CV (Synflorix™, GlaxoSmithKline plc., UK) it was 46% and for PCV13 (Prevenar 13, Pfizer Inc., USA) it was 86%. For those cases less than 2 years of age, the potential coverage provided by both PCV7 and PHiD-CV was 53%, increasing to 87% for PCV13.
Sequence types and antimicrobial susceptibility
Reduced susceptibility to penicillin was observed for 25% of the isolates, 86% of which occurred in children <3 years of age. One isolate (serotype 14) demonstrated high-level penicillin resistance and caused an infection in a 1-year-old boy. Four serotypes were associated with reduced susceptibility to penicillin, the most common being serotype 14 (n=3), followed by 19A (n=2), 19F (n=1) and 9V (n=1). Intermediate resistance to cefotaxime was observed for 3.6% of isolates. Resistance to erythromycin and clindamycin was observed for 18% and 11% of isolates, respectively. All isolates were sensitive to tigecycline. MDR was evident for 11% of isolates and all were members of serogroup 19. Twenty-one STs were identified in total ( Table 2 ). The predominant clone associated with serotype 3 was ST180 (n=3) and the genetically unrelated serotype 3 ST458 (n=1) was also identified. A high level of variation was observed among the clones associated with serotype 19F (ST420, ST425, ST73, ST87 and ST3508), all of which were considered to be unrelated to each other following eBURST analysis (data not shown 
Discussion
This is the first report on the serotype distribution of S. pneumoniae causing OM in children in Ireland. In order to determine the serotypes associated with these infections, a combination of multiplex PCR and traditional serological methods was employed. During the multiplex PCR validation process using control collections of isolates, no crossreactivity with organisms other than S. pneumoniae was identified and the serogroup/serotype of all S. pneumoniae isolates targeted by the scheme was accurately determined, although three exceptions were initially identified. Nonetheless, further analysis confirmed the PCR result as being accurate. Due to the less labourious nature of the PCR method, in addition to the absence of a DNA purification step, it was considered to be feasible and more efficient to employ this method in combination with serological methods for the serotype determination of isolates in our laboratory setting. A limitation of this PCR method is its inability to differentiate between the commonly occurring serotypes 6A, 6B and the more recently described 6C [16] . In addition, this method does not identify serotype 19A, which is a frequently occurring serotype among OM isolates in this study. For these and the other serotypes not targeted with the multiplex PCR assays, confirmation to the serotype level using traditional serological methods and/ or PCR in the case of 6C, is required.
Efforts are being focused in a number of countries to reduce antibiotic consumption, as the levels of antimicrobial resistance are developing more rapidly than the development of new antimicrobials. However, the use of a pneumococcal conjugate vaccine reduced otitis-associated antimicrobial consumption by 20% [17] . Of the four serotypes associated with reduced susceptibility to penicillin in this study, three of these are contained in PCV7 and PHiD-CV, while all are contained in PCV13. Reduced susceptibility to penicillin (25% of isolates) was more common than resistance to erythromycin (18%) and clindamycin (11%). This level of penicillin resistance is half that observed (50%) for OM isolates in Spain in the 1990s, where OM clinical failures were associated with 90% penicillin resistance [18] . Conversely, penicillin resistance in Ireland is considerably higher than the 1.5% level observed for S. pneumoniae isolates in the Netherlands [19] , a country with one of the lowest rates of antimicrobial prescribing in the world [20] .
In the present study, the top five ranked serotypes were 3, 19F, 19A, 14 and 6A, which are also the most common causes of OM worldwide [21] . The potential coverage provided by PCV7 and PHiD-CV was similar at 43% and 46%, respectively. This increased to 86% for PCV13. In the US, since PCV7 introduction, a serotype 3 clone, namely, Netherlands 3 -31(ST180), has become more prevalent and is emerging as a common vaccine replacement serotype causing disease [1, 21, 22] . The present study indicates that this particular serotype 3 clone, susceptible to all antibiotics tested, was most commonly associated with OM in Dublin prior to PCV7 vaccine introduction. This finding -3 is a widely disseminated clone commonly associated with penicillin resistance. It seems to have emerged in Spain in the 1980s and has established itself as a common cause of infections in a number of countries, such as France, Denmark, Germany and the Netherlands [26] [27] [28] [29] [30] . The two serotype 6A clones, ST65 and ST2611, were also from diverse lineages and, unlike the MDR 6A clones in OM that are emerging in Israel [31] , neither clone displayed resistance to the antimicrobials tested.
Overall, the phenotype and genotype of S. pneumoniae isolates causing OM in Dublin is similar to that observed in a number of other countries. However, a limitation of the study is the small number of isolates available for characterisation over a relatively short period confined to one region in Ireland. For this reason, the results should be interpreted with some degree of caution. However, this study has provided important baseline information, for the most part, prior to PCV7 introduction, when serotype replacement due to vaccine introduction is unlikely to have occurred. It is interesting that three of the most common serotypes causing OM are not contained in PCV7, although cross-protection against serotype 6A may be provided, as evidenced by the decline of this serotype since PCV7 introduction in the US [32] . However, serotypes 3, 6A and 19A are contained in PCV13, so infections caused by these serotypes are potentially vaccine-preventable.
In conclusion, this study reinforces the importance of continued monitoring of the epidemiology of S. pneumoniae causing OM in Ireland, especially in the post-PCV7 vaccine era, in order to determine if serotype replacement occurs and to monitor antibiotic resistance. Such monitoring will guide future vaccine and treatment policies.
